Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.30 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14393604 | 0.90 | MGLL (0.33) | MGLLADORA2A | |
| SCHEMBL13625945 | 0.90 | MGLL (0.33) | MGLLADORA2A | |
| SCHEMBL13625607 | 0.89 | ADORA2A (0.43) | ADORA2A | |
| SCHEMBL14393445 | 0.87 | ADORA2A (0.33) | ADORA2A | |
| SCHEMBL14393332 | 0.87 | ADORA2A (0.32) | ADORA2A | |
| SCHEMBL13625741 | 0.87 | ADORA2A (0.32) | ADORA2A | |
| SCHEMBL13625679 | 0.87 | ADORA2A (0.33) | ADORA2A | |
| SCHEMBL14393331 | 0.87 | ADORA2A (0.32) | ADORA2A | |
| SCHEMBL14393617 | 0.86 | GRIN2B (0.32) | ADORA2AHTT | |
| SCHEMBL13625864 | 0.86 | ADORA2A (0.33) | ADORA2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270373-A1 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | ADENOSINE THERAPEUTICS, LLC | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270373-A1 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | ADORA2A, ADORA1, ADORA3 | MGLL 2377/4885ADORA2A 1/4885CCNE2 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.